Drug delivery with PEGylaton

EBR - European Biopharmaceutical Review

Volumn , Issue SPRI, 2008, Pages 96-104

  Bruckdorfer, Thomas ^a  

^a IRIS Biotech ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE MACROGOL; DNA; GLYCOLIC ACID; MACROGOL; NANOPARTICLE; PEG FILGRASTIM; PEGADEMASE; PEGAPTANIB; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGVISOMANT; POLYLACTIC ACID; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EXCRETION; DRUG FORMULATION; DRUG MARKETING; HUMAN; REVIEW;

EID: 59749101945     PISSN: 1364369X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, Molema G, Scaria PV and Woodle MC, Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabalized nanoparticle; Nucleic Acid Research 32(19) e149, 2004
2. Ogris M, Walker G, Blessing T, Kircheis R and Wagner E, Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycolpolyethyleneimine - DNA complexes, Journal of Controlled Release 91, pp173-181, 2003
3. Trimaille T, Mondon K, Gurny R and Möller M, Novel polymeric micelles for hydrophobic grug delivery based on biodegradable poly(hexyl-substitude lactides); International Journal of Pharmaceutics 319, pp147-154, 2006
4. Veronese FM, Peptide and protein PEGylation: a review of problems and solutions, Biomaterials 22, pp405-417, 2001
5. Haag R and Kratz F, Polymer Therapeutics: Concepts and applications; Angew Chem 118, pp1,218-1,237, 2006;
6. Angew Chem Int Ed 45, pp1,198-1,215, 2006
7. Chapman AP, PEGylated antibodies and antibody fragments for improved therapy: a review; Advanced Drug Delivery Reviews 54, pp531-545, 2002
8. Levy Y et al, Adenosine deaminase deficiency with late onset or recurrent infections; response to treatment with polyethylene glycol modified adenosine deaminase; J Pediatr 113, pp312-317, 1988
9. Duncan R, The dawning era of polymer therapeutics; Nature Reviews Drug Discovery 2, pp347-360, 2003
10. Veronese FM, PEGylation, successful approach to drug delivery, Drug Discovery Today 10(21), pp1,451-1,457, 2005
11. Bailon P et al, Rational design of a potent, long lasting form of interferon: a 40kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C, Bioconjug Chem 12, pp195-202, 2001
12. Painter PC and Coleman MM, Fundamentals of Polymer Science, CRC Press 22, 1997
13. Roberts MJ, Bentley MD and Harris JM, Chemistry for peptide and protein PEGylation, Advanced Drug Delivery Reviews 54, pp459-476, 2002
14. Veronese FM and Harris JM (eds), Peptide and protein PEGYlation III: advances in chemistry and clinical applications; Advanced Drug Delivery Reviews 60, pp1-97, 2008
15. Yankeelov Jr AJA, Modifications of arginines by diketones, Method Enzymol B25, pp566-84, 1972
16. Akihito S, Maeda H, Kai Y and Ono K, Polyethylene glycol derivatives, modified peptides and production thereof, EP 0.340.741
17. Goodson RJ and Katre NN, Site-directed pegylation of recombinant interleukine-2 at its glycosylation site; Biotechnology 8, pp343-346, 1990
18. Morpurgo M, Veronese F, Kachensky D and Harris JM, Preparation and characterization of poly(ethylene glycol) vinyl sulfone; Bioconjug Chem 4, pp314-318, 1993